Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
4553.T
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
+241%
96.51
vs 28.34
Q3.23
+70%
44.75
vs 26.35
Q4.23
+745%
92.77
vs -14.38
Q1.24
+2044%
94.56
vs 4.41
Q2.24
+16%
111.64
vs 96.51
Q3.24
-52%
21.53
vs 44.75
Q4.24
+77%
163.91
vs 92.77
Q1.25
-6%
88.61
vs 94.56
Q2.25
-43%
63.46
vs 111.64
Q3.25
+188%
62.02
vs 21.53
Sales Growth
YoY
Current
Estimates
Q2.23
+20%
54.5B vs 45.4B
Q3.23
+17%
52.8B vs 45.1B
Q4.23
+22%
60.9B vs 49.9B
Q1.24
-13%
59.6B vs 68.5B
Q2.24
+15%
62.6B vs 54.5B
Q3.24
+15%
60.8B vs 52.8B
Q4.24
+15%
70.3B vs 60.9B
Q1.25
+10%
65.9B vs 59.6B
Q2.25
+8%
67.8B vs 62.6B
Q3.25
+9%
66.3B vs 60.8B
Return on Equity
QoQ
Q2.23
+3%
0.03
vs 0
Q3.23
+2%
0.02
vs 0.03
Q4.23
+3%
0.03
vs 0.02
Q1.24
+3%
0.03
vs 0.03
Q2.24
+3%
0.03
vs 0.03
Q3.24
+1%
0.01
vs 0.03
Q4.24
+5%
0.05
vs 0.01
Q1.25
+3%
0.03
vs 0.05
Institutionnal Ownership
Forecast
325%2026-Revenue
302%2026-EPS
401%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Relative Strength
4553.T
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
JPX
20.00Â ( 0.66%)
Relative Strenght
Volume Buzz
-1%
Earning Acce
No
Dist 52w H.
10%Quote Panel
Key Metrics
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How 4553.T compares to sector?